In the same issue, a study of short-term

travelers from A

In the same issue, a study of short-term

travelers from Australia to Asia analyzing paired pre-travel and post-travel sera showed a much lower incidence of 2.19 new hepatitis B Etoposide infections per 10,000 travel days.[2] This is in agreement with a recent study of Danish travelers where the monthly incidence of HBV was estimated to be 10.2 per 100,000.[3] Multiple factors, including HBV prevalence in the destination country, visiting friends and relatives (VFR) status, risk activities, or medical care during travel, all impact risk of HBV acquisition.[1] These at-risk travelers should be offered hepatitis B vaccination. Pre-travel consultation is also an opportunity to identify previously undiagnosed HBV infection in travelers known to be at risk of HBV infection as underlined in one article published in the 20.1 issue of the Journal. The authors evaluated the behavior of travel medicine practitioners in Boston, MA, as it relates to screening Venetoclax research buy travelers for hepatitis B.[4] In this study, provider behavior in relation to testing for HBV as well as characteristics of those tested and immunized for HBV were analyzed over a 25-month period: 16% of patients were born in HBV-risk countries, only 25% had previous HBV test results at their travel clinic appointment and 11% had tests performed at their travel clinic visit. Among

230 travelers tested during their travel clinic visit, 3.3% were HBV infected (HBsAg-positive), 43.6% immune (anti-HBs-positive), and 59.2% susceptible by serologic testing. The US National Health and Nutrition Survey data from 1999 to 2006 showed an overall

prevalence rate in the United States for chronic HBV infection of 0.27%,[5] indicating that in this group of US travel clinics in Boston, patients are more likely to be travelers at higher previous risk of HBV infection. Travel clinics that see a larger proportion of VFR travelers may be predicted to have similar results. The results of these studies offer some hope 3-mercaptopyruvate sulfurtransferase for progress in reducing hepatitis B infection and its long-term sequelae, and also reveal that there is significant room for improvement in our educational and clinical practices. Carriers are under diagnosed in the United States.[6] In addition, it is estimated that only 4% to 5% of chronically HBV-infected patients are screened, enter a health system, and obtain treatment.[6] In 2008, the Centers for Disease Control and Prevention (CDC) issued guidelines recommending HBV screening for all persons born in geographic regions with an HBsAg prevalence of >2% (many of whom are VFR or last-minute travelers), all US-born persons who were unvaccinated as infants and whose parents were born in regions of high HBV endemicity (≥8% HBsAg prevalence), and individuals with parenteral risk factors.

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>